Temozolomida y disminución de crisis epilépticas en gliomas benignos

August 2011
Revista Neurocirugia;ago2011, Vol. 22 Issue 4, p354
Academic Journal
No abstract available.


Related Articles

  • Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. Kim, Il; Park, Chul-Kee; Heo, Dae; Kim, Chae-Yong; Rhee, Chang; Nam, Do-Hyun; Lee, Seung; Han, Jung; Lee, Se-Hoon; Kim, Tae; Kim, Dong-Wan; Kim, Jeong; Paek, Sun; Kim, Dong; Kim, In; Kim, Yu; Kim, Jee; Park, Byung-Joo; Jung, Hee-Won // Journal of Neuro-Oncology;Jul2011, Vol. 103 Issue 3, p595 

    prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma. The study...

  • Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Niyazi, Maximilian; Karin, Ivan; Söhn, Matthias; Nachbichler, Silke B.; Lang, Peter; Belka, Claus; Ganswindt, Ute // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background Re-irradiation is a reasonable second treatment option for patients with recurrent malignant glioma (MG) after previous radio(chemo)therapy. However, only limited data is available allowing for a precise selection of patients suitable for re-treatment in regard to safety and efficacy....

  • Going past the data for temozolomide. Villano, J.; Letarte, Nathalie; Bressler, Linda // Cancer Chemotherapy & Pharmacology;Apr2012, Vol. 69 Issue 4, p1113 

    The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the...

  • Evaluation of the synergetic radio-chemotherapy effects of the radio labelled cisplatin for the treatment of glioma. Soares, Marcela; Mattos, Juliana; Pujatti, Priscila; Leal, Alexandre; dos Santos, Wagner; dos Santos, Raquel // Journal of Radioanalytical & Nuclear Chemistry;Apr2012, Vol. 292 Issue 1, p61 

    The proposal of this work was to investigate the effect of the radioactive (NH)PtCl, cis-diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of CDDP*...

  • Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway Gramatzki, Dorothee; Herrmann, Caroline; Happold, Caroline; Becker, Katrin Anne; Gulbins, Erich; Weller, Michael; Tabatabai, Ghazaleh // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background/Aims: Resistance to genotoxic therapy is a characteristic feature of glioma cells. Acid sphingomyelinase (ASM) hydrolyzes sphingomyelin to ceramide and glucosylceramide synthase (GCS) catalyzes ceramide metabolism. Increased ceramide levels have been suggested to enhance...

  • Nucleic Acids in Human Glioma Treatment: Innovative Approaches and Recent Results. Catuogno, S.; Esposito, C. L.; Quintavalle, C.; Condorelli, G.; Franciscis, V. de; Cerchia, L. // Journal of Signal Transduction;2012, p1 

    Gliomas are the most common primary central nervous system tumors with a dismal prognosis. Despite recent advances in surgery, radiotherapy, and chemotherapy, current treatment regimens have a modest survival benefit. A crucial challenge is to deliver drugs effectively to invasive glioma cells...

  • Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. Felix, Francisco; Araujo, Orlandira; Trindade, Karine; Trompieri, Nadia; Fontenele, Juvenia // Journal of Neuro-Oncology;Jan2014, Vol. 116 Issue 2, p261 

    Diffuse intrinsic pontine glioma is a pediatric oncologic disease with dismal prognosis and no effective treatment. Since 2007, our patients have been using valproic acid as prophylactic anticonvulsant. We have undertaken a retrospective study in order to evaluate the influence of valproate in...

  • Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. Kim, Young-Hoon; Park, Chul-Kee; Cho, Won; Kim, In; Moon, Seyoung; Choe, Gheeyoung; Park, Sung-Hye; Kim, Il; Kim, Dong; Jung, Hee-Won; Lee, Min; Bae, So; Cha, Seung; Kim, Chae-Yong // Journal of Neuro-Oncology;Jul2011, Vol. 103 Issue 3, p503 

    This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with WHO grade III gliomas. Thirty-three adult patients with WHO grade III glioma...

  • Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. Dong, Jun; Zhou, Guanghua; Tang, Dongfang; Chen, Yanming; Cui, Baoqian; Dai, Xingliang; Zhang, Jinshi; Lan, Qing; Huang, Qiang // Journal of Cancer Research & Clinical Oncology;Dec2012, Vol. 138 Issue 12, p2079 

    Background: Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy. In an effort to develop new therapeutic choices to treat malignant gliomas, we have designed slow-releasing microspheres that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics